Awakn Life Sciences receives UK backing for ketamine therapy
Drug Discovery World
JULY 11, 2022
Biotechnology company Awakn Life Sciences has received funding from Innovate UK to help it advance its ketamine-assisted therapy programme to market in the UK and US. . Awakn Life Sciences has developed a ketamine-assisted therapy programme for treating alcohol use disorder (AUD). The company plans to work with clinical research organisation (CRO) Veristat to deliver its programmes. .
Let's personalize your content